ATC codes:
V03AF01
EMLc
Indication
Osteosarcoma of bone and articular cartilage of other specified sites
ICD11 code:
2C21.Y
INN
Mesna
Medicine type
Chemical agent
List type
Complementary
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
100 mg per mL in 4 mL ampoule ;
100 mg per mL in 10 mL ampoule
Oral > Solid: 400 mg ; 600 mg
Oral > Solid: 400 mg ; 600 mg
EML status history
First added in 2015
(TRS
994)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for mesna on the complementary list of the EML and EMLc for use in treatment protocols for osteosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for osteosarcoma is attached.